February 2020 Vol 6 No 1

First-Line Calquence-Based Combination Therapy for Patients with Chronic Lymphocytic Leukemia
Calquence, a new-generation targeted therapy recently approved for the treatment of CLL, has shown good results in a 3-drug combination therapy.
Addressing the Negative Associations with Lung Cancer
Lung Cancer
Dr. Joan Schiller, like many cancer care advocates, is working to change the negative attitudes and misconceptions about lung cancer, which is often seen as being caused by the patient, but in reality affects many people who never have smoked.
Staging of Non–Small-Cell Lung Cancer: A Guide for Patients
Lung Cancer
Knowing the stage of lung cancer helps oncologists to plan the best treatment plan for each patient. This first article in the series explains how the most common type of lung cancer is staged.
First Love Yourself: Picking Up the Pieces
Patient StoriesLymphoma
When 24-year-old Mia Brister was diagnosed with Hodgkin lymphoma, it was as if her whole world had shattered. She had to learn to be kind with herself to put her life together again.
Nature Photography Is Healing My Spirit
Art Therapy
After being diagnosed with a genetic mutation associated with immune disorders, including myelodysplastic syndromes and leukemia, Marit Chrislock had to give up her long-distance running in the Colorado mountains, using photography to express her love of nature.
The Rite of Passage
From Your Navigator
Within the oncology world, there is a new controversy thick in the air—"Ringing of the bell."
Healthy Food Habits for Colon Cancer Risk Reduction and Survivorship
Nutrition & CancerColorectal Cancer
Oncology dietitian Julie Lanford offers tips on how to reduce the risk of colon cancer, as well as strategies for survivors during and after cancer treatment.
New All-Oral Combination Therapy for CLL Shows Impressive Results
A new study using a combination of the 2 oral drugs, Copiktra and Venclexta, showed promising results for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma.
Brukinsa, a New BTK Inhibitor, Shows Impressive Results in Patients with CLL
Brukinsa, which was approved for use in patients with mantle-cell leukemia in late 2019, has also showed promising results in 2 recent clinical trials of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), including patients with high-risk genetic abnormalities.
From Fly-Fishing to “Ringing the Bell”
Issue Introductions
Hello everyone and welcome to our February 2020 issue of CONQUER: the patient voice! Once again, we have packed many articles into this new issue to empower you with information, provide hope through inspirational stories from others, and perhaps help you look at the world with a different perspective.
Page 1 of 2
Results 1 - 10 of 17

Subscribe to CONQUER: the patient voice

Receive timely cancer news & updates, patient stories, and more.

Race or Ethnicity
Profession or Role
Primary Interest
Other Interests